Tenax Therapeutics’ heart-failure drug misses primary goal in Phase 3 trial, shares tumble

Tenax Therapeutics announced that its experimental oral levosimendan failed to meet the primary efficacy endpoint in the Phase 3 LEVEL study, which evaluated treatment for a form of heart failure linked to elevated pulmonary blood pressure.

The trial showed the drug improved six‑minute walk distance by 14 meters versus 10.4 meters for placebo, a difference that was not statistically significant, leading the company to deem the result negative.

Following the announcement, Tenax’s stock dropped sharply, falling about 84% to roughly $2 per share in early trading.

The outcome underscores the challenges of developing therapies for pulmonary‑hypertension‑related heart failure and may prompt the company to reassess its development strategy.